Madrigal Pharmaceuticals Stock (NASDAQ:MDGL), Quotes and News Summary

Q: What sector and industry does Madrigal Pharmaceuticals (MDGL) operate in?

Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Madrigal Pharmaceuticals Stock (NASDAQ: MDGL) stock price, news, charts, stock research, profile.

Open	$206.400
Close	$205.250
Volume / Avg.	234.068K / 555.804K
Day Range	203.860 - 208.740
52 Wk Range	119.760 - 311.560
Market Cap	$4.374B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	41
Short Interest	23.18%
Days to Cover	9.88

Recent News

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.

Avi Kapoor

FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring

FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease. Availability is slated for April in the U.S.

Vandana Singh

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trend

Feb

Mar

Apr

May

Buy

Hold

Sell

Strong Sell

Analyst Rating

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Madrigal Pharmaceuticals (MDGL) stock?

You can purchase shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) through any online brokerage.

View our list of the best stock brokerages.

Who are Madrigal Pharmaceuticals's (MDGL) competitors?

Other companies in Madrigal Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and Alkermes (NASDAQ:ALKS).

What is the target price for Madrigal Pharmaceuticals (MDGL) stock?

The latest price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) was reported by B. Riley Securities on Friday, May 10, 2024. The analyst firm set a price target for 200.00 expecting MDGL to fall to within 12 months (a possible -2.56% downside). 34 analyst firms have reported ratings in the last year.

Current Stock Price for Madrigal Pharmaceuticals (MDGL)?

The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $205.25 last updated May 10, 2024 at 4:00 PM EDT.

Does Madrigal Pharmaceuticals (MDGL) pay a dividend?

There are no upcoming dividends for Madrigal Pharmaceuticals.

When is Madrigal Pharmaceuticals (NASDAQ:MDGL) reporting earnings?

Madrigal Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 6, 2024.

Is Madrigal Pharmaceuticals (MDGL) going to split?

There is no upcoming split for Madrigal Pharmaceuticals.

What sector and industry does Madrigal Pharmaceuticals (MDGL) operate in?

Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-